期刊文献+

急性冠脉综合征合并糖尿病患者血浆TF、TFPI水平的研究 被引量:1

A study of TF and TFPI level in patients with acute coronary syndrome and non-insulin-dependent diabetes mellitus
下载PDF
导出
摘要 目的:探讨急性冠脉综合征(ACS)合并或不合并非胰岛素依赖性糖尿病(NIDDM)患者血浆组织因子(TF)?组织因子途径抑制物(TFPI)水平的特点?方法:选择ACS合并NIDDM患者22例?ACS不合并NIDDM患者21例?单纯NIDDM患者23例及正常对照组20例,应用ELISA法检测各组的TF?TFPI抗原水平,对比各组间指标,并对TF?TFPI水平进行相关性分析?结果:ACS合并或不合并NIDDM患者的TF和TFPI抗原水平皆显著高于对照组(P<0.01),且ACS合并NIDDM者高于不合并NIDDM者(P<0.05)及单纯NIDDM者(P<0.01);TF与TFPI抗原水平呈显著正相关(r=0.36, P<0.01)?结论:ACS患者存在凝血功能的异常状态,而ACS合并NIDDM患者的凝血功能异常更为明显,TF和TFPI水平升高可能是NIDDM患者发生ACS的预报因子? Objective: To investigate the abnormal state of tissue factor(TF) and tissue factor pathway inhibitor(TFPI) in patients with acute coronary syndrome(ACS) and non-insulin-dependent diabetes mellitus (NIDDM). Methods: Patients were divided into four groups: ACS with NIDDM group, ACS without NIDDM group, NIDDM group and the control group. Plasmic TF and TFPI were assayed by ELISA. Results: The TF and TFPI levels of ACS patients with or without NIDDM were both significantly higher than those of the control group (P<0.01), and those of ACS with NIDDM were higher than those of ACS without NIDDM(P<0.05). There was a positive correlation between TF and TFPI(r=0.36, P<0.01). Conclusion: Abnormal states of coagulation systems are present in patients with ACS, especially in those with NIDDM. The levels of TF, TFPI may be predictive factors of ACS in patients with NIDDM. [
出处 《山东大学学报(医学版)》 CAS 2004年第3期277-279,286,共4页 Journal of Shandong University:Health Sciences
关键词 冠状动脉疾病 糖尿病 凝血致活酶 凝血致活酶抑制物 Coronary disease Diabetes mellitus Thromboplastin Thromboplastin inhibitor
  • 相关文献

参考文献8

  • 1Selwyn AP. Prothrombotic and antithrombotic pathways in acute coronary syndromes[J]. Am J Cardiol,2003, 91(12A):3H.
  • 2Falciani M, Gori AM, Fedi S, et al. Elevated tissue factor and tissue factor pathway inhibitor circulating levels in ischaemic heart disease patients[J]. Thromb Haemost, 1998, 79(3):495.
  • 3Keen H, Clark C, Laakso M. Reducing the burden of diabetes: managing cardiovascular disease[J]. Diabetes Metab Res Rev, 1999, 15:186.
  • 4Soejima H, Ogawa H, Yasue H, et al. Heightened tissue factor associated with tissue factor pathway inhibitor and prognosis in patients with unstable angina[J]. Circulation, 1999, 99(22):2908.
  • 5Galajda P, Martinka E, Kubisz P, et al. Hemostasis in patients with diabetes mellitus[J]. Vnitr Lek, 1996,42(11):776.
  • 6Zumbach M, Hofmann M, Borcea V, et al. Tissue factor antigen is elevated in patients with microvascular complications of diabetes mellitus[J]. Exp Clin Endocrinol Diabetes, 1997, 105(4): 206.
  • 7Khechai F, Ollivier V, Bridey F, et al. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes[J]. Arterioscler Thromb Vasc Biol, 1997, 17:2885.
  • 8Bajaj MS, Ameri A, Bajaj SP. Tissue factor pathway inhibitor-a regulator of tissue factor induced coagulation[M]. In: Anti-coagulants: Physiologic, pathologic and pharmacologic. Green D (ed). CRC Press, FL 1994.41.

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部